SS 03 - GU 1: Advances in Localized Prostate Cancer

Presentations

• 02:30pm - 02:40pm PT

  Phase 3, Randomized, Placebo Controlled Clinical Trial of CAN-2409+Prodrug in Combination with Standard of Care External Beam Radiation (EBRT) for Newly Diagnosed Localized Prostate Cancer

  Speaker: Glen Gejerman, MD, MBA - Hackensack University Medical Center, Hackensack
• 02:40pm - 02:50pm PT

  Stereotactic Radiotherapy in 3 Fractions for Localized Prostate Cancer

  Speaker: Giuseppe Sanguineti, MD, Mr - Regina Elena National Cancer Institute, Rome
• 02:50pm - 03:00pm PT

  Two-Year Clinical Outcomes Following Ablative Radiotherapy for Unfavorable Prostate Tumors (ABRUPT)

  Speaker: Stefano Arcangeli, MD - University of Milan Bicocca, Milan
• 03:00pm - 03:10pm PT

  Outcomes Following Radiation Therapy and Radical Prostatectomy in Patients with High Risk Prostate Cancer in a Similar Access System

  Speaker: Abhishek Kumar, MD, MAS - The Oncology Institute of Hope and Innovation, Cerritos
• 03:10pm - 03:20pm PT

  Phase III Study of Hypofractionated, Dose Escalation Radiotherapy vs. Conventional Pelvic Radiation Therapy followed by High Dose Rate Brachytherapy Boost for High Risk Adenocarcinoma of the Prostate (PCS VI)

  Speaker: Tamim Niazi, MD - McGill University, Montreal
• 03:20pm - 03:30pm PT

  Conventional vs. Hypofractionated, Radiotherapy for High-Risk Prostate Cancer: 10-Year Outcomes of the Randomized, Non-Inferiority, Phase 3 PCS5 Trial

  Speaker: Tamim Niazi, MD - McGill University, Montreal
• 03:30pm - 03:35pm PT

  5-Year Results of a Prospective, Non-Randomized Controlled Study: Comparison of the Efficacy and Safety of ADT + Docetaxel vs. ADT + Novel Hormone Therapy in High Gleason Score Non-Metastatic Prostate Cancer Patients Receiving Radiotherapy

  Speaker: Mingwei Ma, MD - Peking University First Hospital, Beijing